Abstract
Colorectal cancer is the third most common cancer worldwide and the second most common cancer in Europe. The role of 18F-FDG (FDG) PET/CT in suspected recurrence, in patients with liver metastases eligible for surgical management, and in treatment response evaluation in colorectal carcinoma is now well established with more data emerging in initial staging of colorectal cancer [1]. FDG PET/CT can influence the management strategies in colorectal patient in up to 30% of the cases [2]. In this context, adequate understanding of the physiological variants, possible artefacts, as well as imaging pitfalls of FDG PET/CT in colorectal carcinoma patients is extremely important.
Access provided by CONRICYT-eBooks. Download chapter PDF
Similar content being viewed by others
Keywords
- Fibrous Dysplasia
- Maximum Intensity Projection Image
- Colorectal Malignancy
- Respiratory Motion Artefact
- Bladder Diverticulum
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
5.1 Introduction
Colorectal cancer is the third most common cancer worldwide and the second most common cancer in Europe. The role of 18F-FDG (FDG) PET/CT in suspected recurrence, in patients with liver metastases eligible for surgical management, and in treatment response evaluation in colorectal carcinoma is now well established with more data emerging in initial staging of colorectal cancer [1]. FDG PET/CT can influence the management strategies in colorectal patient in up to 30% of the cases [2]. In this context, adequate understanding of the physiological variants, possible artefacts, as well as imaging pitfalls of FDG PET/CT in colorectal carcinoma patients is extremely important.
5.2 Physiological Variants
A thorough understanding of sites of physiological uptake in abdomen and pelvis (Fig. 5.1) is an essential prerequisite to interpret FDG PET/CT scans in colorectal carcinoma. Physiologically increased FDG uptake is seen in the diaphragmatic cruces in conditions of increased abdominal breathing effort (Fig. 5.2). Perhaps FDG uptake in the gastrointestinal tract is the most variable (Fig. 5.3) ranging from no discernible uptake above background to diffuse intense FDG uptake [3] and may be affected by a number of factors ranging from smooth muscle contraction to mucosal metabolic activity [4].
5.3 Artefacts and Imaging Pitfalls
Potential artefacts and imaging pitfalls in the interpretation of FDG PET/CT in colorectal cancers are mostly related to abdomen and pelvic regions. They can be broadly grouped into technical: organ or pathology specific and treatment related.
5.4 Technical Artefacts
5.4.1 Misregistration
Misregistration is an incorrect superimposition of PET and CT data on a fused image, potentially resulting in an abnormality being ascribed to the wrong structure. It may be due to breathing, patient motion, bowel motility, or distension of the bladder and can result in both false-positive or false-negative PET findings if not identified and corrected appropriately [5]. Respiratory motion artefacts (Fig. 5.4) predominantly affect structures close to the diaphragm especially liver lesions and basal lung lesions. Review of PET alone images and identification of any associated CT abnormalities would be helpful. Patient motion and consequent artefacts are minimised by (a) placing the patient in a comfortable position, (b) instructing patient not to move during the study, and (c) having the patients empty their bladder before the start of the study. Acquisition of PET images from pelvis to head, after CT acquisition, also helps in reducing artefacts due to bladder filling (Fig. 5.5). Bowel peristalsis and positional changes also result in misregistration (Fig. 5.6), particularly in the small bowel. Potential use of antiperistaltic agents like N-butylscopolamine exists but requires further studies and validation [6].
5.4.2 Partial Volume Effect
In PET scanners, spatial resolution effects can lead to underestimation of activity in small lesions with consequent pitfalls in assessing small moderately active lesions, where modest changes in apparent activity may influence interpretation [7].
5.4.3 Attenuation Correction Artefacts
It is seen in the presence of highly attenuating objects like metallic prostheses/stents, high-density drainage tubes, and dense intravenous contrast in the path of the CT beam (Fig. 5.7). These artefacts can easily be identified by comparing the attenuation-corrected images with the uncorrected images. [8].
5.4.4 Truncation Artefacts
Truncation artefacts in PET/CT are essentially due to the difference in size of the axial field of view between the CT (50 cm) and the PET (70 cm) tomographs. Modern scanners mitigate these effects by reconstructing attenuation correction maps to 70 cm using data extrapolation methods [9, 10].
5.5 Organ- and Pathology-Specific Pitfalls
5.5.1 Liver
Physiological FDG uptake is homogeneous/uniformly mottled and slightly greater than splenic uptake (Fig. 5.8). The significance of suspicious focus of FDG uptake in the liver can be ascertained by checking whether the uptake is distinctly discernible in the maximum intensity projection image and whether there is a corresponding lesion in contrast-enhanced CT or MRI images (Fig. 5.9). False-positive and false-negative FDG uptake in the liver [11, 12] is described in Table 5.1.
5.5.2 Spleen, Pancreas, and Adrenals
In general, splenic uptake greater than the liver is considered significant. Isolated focal increased FDG uptake in the pancreas in a case of colorectal malignancy is unlikely to be metastatic (Fig. 5.10). Increased FDG uptake (focal/diffusely increased) in the spleen [11], pancreas [13–14], and adrenals [15] is listed in Table 5.2.
5.5.3 Stomach
Diffuse FDG uptake is often seen associated with gastritis. Focal FDG uptake in stomach if clinically significant can be further evaluated with endoscopy (Fig. 5.11).
5.5.4 Colon and Small Bowel
Oral contrast is particularly useful in characterising small bowel pathology and is routinely used in FDG PET/CT; however, rectal contrast is not routinely used. Careful correlation with adjunct CT findings is crucial in interpretation of FDG avidity in the colon (Fig. 5.12). Mostly characteristic CT findings help in identifying non-malignant causes of FDG uptake in the colon including appendicitis, diverticulitis, and focal abdominal or pelvic abscesses. Focal intense FDG activity in the colon (Fig. 5.13) may represent neoplastic lesion in up to 68% cases and hence warrants further evaluation with colonoscopy or CT colonography [16]. Intense large and small bowel uptake may be seen in diabetic patients on metformin (Fig. 5.14) [17].
5.5.5 Urinary Tract
Focal pooling of the tracer in the renal calyces or pelvis, dilated or redundant ureters, or bladder diverticula can mimic pelvic or retroperitoneal lymph node metastasis (Fig. 5.15). Careful review of the MIP image for the characteristic course of ureteric activity and search for coexistent anatomical lesion on CT part are helpful. The use of loop diuretics and delayed imaging helps to tackle the effects of radioactive urine in the urinary tract.
5.5.6 Reproductive System
In females, ovaries as well as uterus show variable physiological uptake depending on the phase of menstrual cycle. In males, prostate and testis may show variable physiological FDG uptake. Correlative anatomical imaging is helpful.
5.5.7 Bone
Bone lesions in the context of colorectal carcinoma have to be interpreted with caution. Sclerosis/lytic changes may not be obvious in CT; also benign mimickers with FDG uptake like Paget’s disease (Fig. 5.16), fibrous dysplasia, and healing fracture exist. Diffuse increase in bone marrow activity is seen following chemotherapy and exogenous marrow stimulation which may make interpretation of bone lesions difficult. Diffuse marrow metastases, although rare, do exist (Fig. 5.17).
5.5.8 Muscle
Muscle metastases/deposits although rare have to be kept in mind (Fig. 5.18), and mimickers include abscess. Often tissue diagnosis is required in such cases especially in the context of cystic muscle metastases. Enthesitis can result in focal FDG uptake at the site of muscle insertion (Fig. 5.19).
5.5.9 Lymph Nodes
An advantage of FDG PET is the ability to depict malignant neoplasms in lymph nodes when the nodes are not pathologically enlarged. False negatives include small-sized lymph nodes (smaller than the resolution of PET scanner), mucinous adenocarcinoma metastases, and post-chemotherapy. False positives include active granulomatous disease such as tuberculosis and sarcoidosis and infection or recent instrumentation resulting in high FDG uptake in involved nodes (Fig. 5.20) [11]. In cases of colorectal malignancies, isolated mediastinal/cervical lymph nodal FDG uptake in the absence of abdominal and pelvic disease should be considered as unrelated to colorectal malignancy unless otherwise proved (Fig. 5.21).
5.5.10 Peritoneum
Increased FDG uptake is frequently seen in peritoneal metastases which appear either nodular or diffuse (Fig. 5.22). The peritoneal disease may not be associated with any abnormal FDG uptake in small-volume disease. False-positive FDG uptake may also be seen in the peritoneum postoperatively due to inflammation. Malignant ascites does not take up FDG.
5.6 Treatment-Related Pitfalls
Surgery, radiation therapy, and chemotherapy forms an integral part of the treatment plan of colorectal malignancies. False-positive FDG uptake following surgery and radiation therapy can occur unless adequate time gap is given with the PET/CT. False negative (no uptake in scan with disease on histopathology) can be seen at primary site, lymph nodes, and liver lesions following chemotherapy. Postsurgical complications like haematoma and surgical abscesses can result in false-positive FDG uptake. Stoma/anastomotic sites can show diffuse or focal FDG uptake, and careful review of CT images for any abnormal thickening or mass lesions is required to clarify possibility of disease involvement (Fig. 5.23). Exogenous marrow stimulation or chemotherapy can result in increased FDG uptake in bone marrow which may make identification of skeletal lesions difficult (Fig. 5.24). Treatment for coexistent disease can also complicate interpretation of FDG avid lesions and requires judicial clinical judgement (Fig. 5.25).
Conclusion
FDG PET/CT is a very useful tool in the management of colorectal malignancies. Careful elucidation of clinical history, minimising technical artefacts, and an adequate understanding of the physiological variants and imaging pitfalls of FDG PET/CT help in accurate reporting of FDG PET/CT in colorectal malignancies.
Key Points
-
A thorough understanding of sites of physiological uptake in the abdomen and pelvis is an essential prerequisite to interpret FDG PET/CT scans in colorectal carcinoma.
-
Respiratory motion artefacts predominantly affect structures close to the diaphragm especially liver lesions and basal lung lesions. Review of PET alone images and identification of any associated CT abnormalities would be helpful.
-
Bowel peristalsis and positional changes also result in misregistration, particularly in the small bowel.
-
Physiological FDG uptake in the liver is homogeneous/uniformly mottled and slightly greater than splenic uptake. The significance of suspicious focus of FDG uptake in the liver can be ascertained by checking whether the uptake is distinctly discernible in the maximum intensity projection image and whether there is a corresponding lesion in contrast-enhanced CT or MRI images.
-
Diffuse FDG uptake is often seen associated with gastritis. Focal FDG uptake in the stomach if clinically significant can be further evaluated with endoscopy.
-
Oral contrast is particularly useful in characterising small bowel pathology and is routinely used in FDG PET/CT; however, rectal contrast is not routinely used.
-
Careful correlation with adjunct CT findings is crucial in interpretation of FDG avidity in the colon.
-
Focal intense FDG activity in the colon may represent neoplastic lesion in up to 68% cases and hence warrants further evaluation with colonoscopy or CT colonography.
-
Intense large and small bowel uptake may be seen in diabetic patients on metformin.
-
Focal pooling of the tracer in the renal calyces or pelvis, dilated or redundant ureters, or bladder diverticula can mimic pelvic or retroperitoneal lymph node metastasis.
-
Ovaries as well as uterus shows variable physiological uptake depending on the phase of menstrual cycle.
-
False-positive FDG uptake following surgery and radiation therapy can occur unless adequate time gap is given with the PET/CT.
-
False negative (no uptake in scan with disease on histopathology) can be seen at primary site, lymph nodes, and liver lesions following chemotherapy.
-
Postsurgical complications like haematoma and surgical abscesses can result in false-positive FDG uptake.
-
Stoma/anastomotic sites can show diffuse or focal FDG uptake, and careful review of CT images for any abnormal thickening or mass lesions is required to clarify possibility of disease involvement.
References
Laurens ST, Oyen WJ. Impact of fluorodeoxyglucose PET/computed tomography on the management of patients with colorectal cancer. PET Clin. 2015;10(3):345–60.
Petersen RK, Hess S, Alavi A, et al. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging. 2014;4(5):471–82.
Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET—CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24(5):1411–31.
Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315–39.
Blake MA, Singh A, Setty BN, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PETCT. Radiographics. 2006;26(5):1335–53.
Emmott J, Sanghera B, Chambers J, Wong WL. The effects of Nbutylscopolamine on bowel uptake: an 18FFDG PET study. Nucl Med Commun. 2008;29(1):11–6.
Corrigan AJ, Schleyer PJ, Cook GJ. Pitfalls and artifacts in the use of PET/CT in oncology imaging. Semin Nucl Med. 2015;45(6):481–99.
Kapoor V, McCook BM, Torok FS. An introduction to PET CT imaging. Radiographics. 2004;24(2):523–43.
Sureshbabu W, Mawlawi O. PET/CT imaging artifacts. J Nucl Med Technol. 2005;33(3):156–61. quiz 63–64
Mawlawi O, Erasmus JJ, Pan T, et al. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm. AJR Am J Roentgenol. 2006;186(5):1458–67.
McDermott S, Skehan SJ. Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT. Abdom Imaging. 2010;35(1):55–69.
Donadon M, Bona S, Montorsi M, et al. FDG-PET positive granuloma of the liver mimicking local recurrence after hepatic resection of colorectal liver metastasis. Hepato-Gastroenterology. 2010;57:138–9.
Bares R, Klever P, Hauptmann S, et al. F18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994;192(1):79–86.
Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by [18F] fluoro-2-deoxy-d-glucose positron emission tomography. Gut. 1995;36(5):771–7.
Culverwell AD, Scarsbrook AF, Chowdhury FU. False-positive uptake on 2-[18F]-fluoro-2-deoxy-D-glucose(FDG)positron-emission tomog- raphy/computed tomography(PET/CT) in oncological imaging. Clin Radiol. 2011;66:366–82.
Treglia G, Taralli S, Salsano M, et al. Prevalence and malignancy risk of focal colorectal incidental uptake detected by 18F-FDG-PETorPET/CT: a meta-analysis. Radiol Oncol. 2014;48(2):99–104.
Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Sasikumar, A., Joy, A. (2017). 18F-FDG PET/CT: Normal Variants, Artefacts, and Pitfalls in Colorectal Cancer. In: Du, Y. (eds) PET/CT in Colorectal Cancer. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-54837-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-54837-1_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54836-4
Online ISBN: 978-3-319-54837-1
eBook Packages: MedicineMedicine (R0)